Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0XPNCZ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
SGN-CD70A
|
|||||
| Synonyms |
SGN 70A; SGN CD70A; SGN-70A; SGN-CD70A; SGNCD-70A; SGNCD70A
Click to Show/Hide
|
|||||
| Organization |
Seagen Inc.
|
|||||
| Drug Status |
Phase 1 (Terminated)
|
|||||
| Indication |
In total 3 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
CD70 antigen (CD70)
|
Antigen Info | ||||
| Payload Name |
PBD dimer
|
Payload Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Conjugate Type |
Reactive Cysteines
|
|||||
| Puchem SID | ||||||
| DrugMap ID | ||||||
| TTD ID | ||||||
| ChEBI ID | ||||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Objective Response Rate (ORR) | 20.00% | Positive CD70 expression (CD70+++/++) | ||
| Patients Enrolled |
CD70-positive MCL or DLBCL including FL3b (expression in at least 50% of the sample)
|
||||
| Administration Dosage |
8 mg/kg (up to a maximum of 200 mg) intravenously once every 3 weeks.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02216890 | Clinical Status | Phase 1 | ||
| Clinical Description | Safety study of SGN-CD70A in cancer patients. | ||||
| Primary Endpoint |
Objective response rate=20.00% (95% CI 5.70-43.70).
|
||||
| Other Endpoint |
Median progression free survival=1.90 months.
|
||||
References